Sign Up Today and Learn More About Alloplex Biotherapeutics Stock
Invest in or calculate the value of your shares in Alloplex Biotherapeutics or other pre-IPO companies through EquityZen's platform.
Alloplex Biotherapeutics Stock (ALLB)
Alloplex Biotherapeutics develops a cellular therapeutic platform for treating cancer.
About Alloplex Biotherapeutics Stock
Founded
2016
Headquarters
Boston, MA, US
Industries
Science and Engineering, Health Care, Biotechnology
Alloplex Biotherapeutics Press Mentions
Stay in the know about the latest news on Alloplex Biotherapeutics
Alloplex’s Suplexa reawakens immune cells to fight cancer
bioworld • Nov 26, 2024
Cancer trial: retraining immune cells offers new hope for patients in personalized medicine breakthrough
morningstar • Oct 31, 2024
Cancer trial: retraining immune cells offers new hope for patients in personalized medicine breakthrough
prnewswire • Oct 31, 2024
Cancer trial: retraining immune cells offers new hope for patients in personalized medicine breakthrough
prnewswire • Oct 31, 2024
Cancer trial: retraining immune cells offers new hope for patients in personalized medicine breakthrough
en • Oct 31, 2024
Alloplex Biotherapeutics Management
Leadership team at Alloplex Biotherapeutics
Founder and CEO
Frank Borriello
Join now and verify your accreditation status to gain access to:
- Alloplex Biotherapeutics Current Valuation
- Alloplex Biotherapeutics Stock Price
- Alloplex Biotherapeutics Management
- Available deals in Alloplex Biotherapeutics and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- Alloplex Biotherapeutics Cap Table and Funding History by Share Class and Liquidity Preferences
- Alloplex Biotherapeutics Revenue and Financials
- Alloplex Biotherapeutics Highlights
- Alloplex Biotherapeutics Business Model
- Alloplex Biotherapeutics Risk Factors
- Alloplex Biotherapeutics Research Report from SACRA Research
Trading Alloplex Biotherapeutics Stock
How to invest in Alloplex Biotherapeutics stock?
Accredited investors can buy pre-IPO stock in companies like Alloplex Biotherapeutics through EquityZen funds. These investments are made available by existing Alloplex Biotherapeutics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Alloplex Biotherapeutics stock?
Shareholders can sell their Alloplex Biotherapeutics stock through EquityZen's private company marketplace. EquityZen's network includes over 360K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 46K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
